Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

OBJECTIVE: To evaluate the risk of serious adverse events among patients with type 2 diabetes mellitus initiating saxagliptin compared with oral antidiabetic drugs (OADs) in classes other than dipeptidyl peptidase-4 (DPP-4) inhibitors. RESEARCH DESIGN AND METHODS: Cohort studies using 2009–2014 data...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:BMJ Open Diabetes Res Care
मुख्य लेखकों: Lo Re, Vincent, Carbonari, Dena M, Saine, M Elle, Newcomb, Craig W, Roy, Jason A, Liu, Qing, Wu, Qufei, Cardillo, Serena, Haynes, Kevin, Kimmel, Stephen E, Reese, Peter P, Margolis, David J, Apter, Andrea J, Reddy, K Rajender, Hennessy, Sean, Bhullar, Harshvinder, Gallagher, Arlene M, Esposito, Daina B, Strom, Brian L
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Publishing Group 2017
विषय:
Epidemiology/Health Services Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574452/
https://ncbi.nlm.nih.gov/pubmed/28878934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2017-000400
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन